Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens.
Lafeuillade
A
A
Jolly
P
P
Chadapaud
S
S
Hittinger
G
G
Lambry
V
V
Philip
G
G
D000225:Adenine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000009:adverse effects*; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D004311:Double-Blind Method; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects*; D012367:RNA, Viral / Q000097:blood; D018119:Stavudine / Q000009:adverse effects*; D000068698:Tenofovir
D019380:Anti-HIV Agents; D008055:Lipids; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D012367:RNA, Viral; D000068698:Tenofovir; D018119:Stavudine; D000225:Adenine